share_log

復星醫藥:海外監管公告-關於以集中競價交易方式回購股份的進展公告

FOSUN PHARMA: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Apr 2 05:51
Summary by Moomoo AI
上海復星醫藥(集團)股份有限公司(簡稱「復星醫藥」)於2024年4月2日發布公告,宣布其回購股份計劃的進展。該計劃於2024年3月27日首次披露,並將在2024年3月26日至9月25日期間實施,預計回購金額為人民幣10億至20億元,回購價格不超過每股30元人民幣。回購目的為用於員工持股計劃或股權激勵。截至目前,公司尚未回購任何股份。復星醫藥承諾將根據市場情況選擇時機進行回購,並及時履行信息披露義務,提醒投資者注意投資風險。
上海復星醫藥(集團)股份有限公司(簡稱「復星醫藥」)於2024年4月2日發布公告,宣布其回購股份計劃的進展。該計劃於2024年3月27日首次披露,並將在2024年3月26日至9月25日期間實施,預計回購金額為人民幣10億至20億元,回購價格不超過每股30元人民幣。回購目的為用於員工持股計劃或股權激勵。截至目前,公司尚未回購任何股份。復星醫藥承諾將根據市場情況選擇時機進行回購,並及時履行信息披露義務,提醒投資者注意投資風險。
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) ISSUED A NOTICE ON APRIL 2, 2024 ANNOUNCING THE PROGRESS OF ITS SHARE REPURCHASE PROGRAM. The plan was first disclosed on March 27, 2024 and will be implemented from March 26 to September 25, 2024. The repurchase amount is expected to be RMB100 billion to RMB20 billion and the repurchase price will not exceed RMB30 per share. The purpose of the repurchase is for employee shareholding schemes or equity incentives. To date, the Company has not repurchased any shares. Resusstar Pharmaceuticals undertakes to select a time to repurchase based on market conditions and to fulfill its obligation to disclose information in a timely manner, reminding investors to be aware of investment risks.
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) ISSUED A NOTICE ON APRIL 2, 2024 ANNOUNCING THE PROGRESS OF ITS SHARE REPURCHASE PROGRAM. The plan was first disclosed on March 27, 2024 and will be implemented from March 26 to September 25, 2024. The repurchase amount is expected to be RMB100 billion to RMB20 billion and the repurchase price will not exceed RMB30 per share. The purpose of the repurchase is for employee shareholding schemes or equity incentives. To date, the Company has not repurchased any shares. Resusstar Pharmaceuticals undertakes to select a time to repurchase based on market conditions and to fulfill its obligation to disclose information in a timely manner, reminding investors to be aware of investment risks.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more